Coridisease,cardiacinvolvementin,1088–1089
Coronaryangiography,Kawasakisyndromeand,987,988f
Coronaryarteries
anatomyof,30–31,30f–31f
aneurysmsof,inKawasakisyndrome,983–984
teachingsfor,993–994
anomalous
originof,318t
repairof,exercisetestingfollowing,400
anomalousaorticoriginof,865–867,868f,873–875,873f
cardiopulmonaryexercisestresstestingof,874
clinicalpresentationof,873
computedtomographicangiographyandmagneticresonanceimagingof,874
diagnostictestingof,873–874
echocardiographyof,873–874,874f
outcomesfor,875
pathophysiologyof,873
surgicalinterventionfor,874–875
surgicaltechniquesfor,875
arterialswitchproceduresand,688–689,689f,693–694,693f
indiagnosticcatheterization,250–251
duplicationof,867
ectopicoriginof,865,866f–867f
left,anatomyof,30,31f
right
anatomyof,30
dominanceof,30,30f
single,875
solitary,867–868,869f
thrombosisof,inKawasakisyndrome
preventionof,990–991
treatmentof,990t,991
intranspositionofthegreatarteries,676–677,678f–679f
Coronaryarterio-venousfistulas
clinicalfeaturesof,937–938
investigationsin,938–940,939f–940f
long-termoutcomesof,941–944,942f–943f
managementof,940–941,941f
morphologyof,936–937,937f–938f
Coronaryartery
abnormalities,classificationsof,986t
fistulaeof,99–100
flowin,fetal,95,95f
Coronarycirculation,endothelialfunctionin,1367
Coronaryorificialatresia,875–876
clinicalpresentationof,875
diagnostictestingof,875–876
outcomesfor,876
pathophysiologyof,875
surgicaltechniquefor,876
Coronarysinusseptaldefect,indiagnosticcatheterization,246
Coronarysinuses
absenceof,withisomericatrialappendages,441
anomaliesof,465f,470,470f
defectsof,506–507,507f–508f
facing,30,30f
leftsuperiorcavalveinto,462,462f
Coronaryveins,anatomyof,31–32,31f
Correlationcoefficient,414
Corticosteroids
incardiopulmonarybypass,231–232
forKawasakisyndrome,989
formyocarditis,1177
Counseling
forcongenitalheartdisease,163
initialsessionof,167–168
styleof,recommended,163
preconception,withcongenitalheartdisease,1442
duringtransition,1453
CPB,Cardiopulmonarybypass
CPET,Cardiopulmonaryexercisetesting
CPVT,Catecholaminergicpolymorphicventriculartachycardia
C-reactiveprotein
inrheumaticfever,1013
systemicarterialdysfunctionand,1371
Credibility,1488–1493
CRISPR/Cas9technology,82
Criss-crosshearts,920–926,920f–926f
Cristadividens,86,86f
Criticalheartdiseases,inneonates,1523,1523t
Cross-sectionalimaging,285–286
fetal,126
Cross-sectionalstudies,417
CRT,Cardiacresynchronizationtherapy
CTC,Cancertherapy-relatedcardiotoxicity
C-typenatriureticpeptide,1358
Cumulativemortalitychart,monitoredinterstagemortalityusing,1507–1509,
1508f
Currarino-Silvermansyndrome,913–914
Currentdataenvironment,403
Cushingsyndrome,hypertensionin,1136
Cusp,945
Cutislaxa,cardiacinvolvementin,1098
Cyanosis,intetralogyofFallot,638–639
Cyanoticcardiacdiseaseinpregnancy,1446
Cycleergometers,388
protocols,388,389f